Memory Disorders Division

Overview

The Memory Disorders Unit and the Frontotemporal Disorders Unit at Massachusetts General Hospital are tertiary care outpatient clinics located on the eighth floor of the Wang Ambulatory Care Center (WACC) of the hospital. We have several specialized services: the Memory Disorders Unit (MDU), the Frontotemporal Disorders Unit (FTD), the Normal Pressure Hydrocephalus clinic, and the Lewy body Dementia clinic. Each unit’s clinical staff consists of board-certified neurologists, geriatric psychiatrists, nurses and social work resource specialists who are fluent in a variety of languages, including French, Hebrew, Italian and Spanish. Complimentary translation and interpretation services in a variety of languages – including sign language – are provided by trained and certified personnel of the Mass General Medical Interpreter Services at all times.

Patients receiving memory care are treated with compassionate, courteous and professional care throughout their diagnostic, consultation and follow-up treatment visits. We require that all patients attend their appointments with a close family member or an individual who can provide reliable information about them. The memory care services that we provide include:

• Comprehensive medical and neurologic assessment, diagnosis and follow-up on pharmacological interventions for dementia symptoms
• Psychiatric evaluation, monitoring and referral to specialists on an “as-needed” basis
• Referral to the Mass General Psychology Assessment Center for neuropsychological examinations and follow-up evaluations
• Referral to the Mass General Genetics Program for genetic counseling for rare cases of inherited memory disorders
• Support groups and social service consultations for family members and caregivers
• Participation in cutting-edge clinical trials and observational studies conducted by the Massachusetts Alzheimer’s Disease Research Center
• Coordination with the International Patient Center for patients from other countries who seek medical care at Mass General

Update on Lecanemab and Donanemab

The US Food and Drug Administration (FDA) approved donanemab (Kinsula) on July 2nd, 2024, for the treatment of early stages of Alzheimer disease. Donanemab joins lecanemab (Leqembi) as the 2nd FDA-approved anti-amyloid antibody treatment approved for Alzheimer disease in the past year.

Learn more about the Mass General Brigham Alzheimer Therapeutics Program

Research

Our clinician-scientists are at the forefront of cutting-edge research to improve memory care, and partner with our patients and research participants in order to discover effective treatments for Alzheimer’s disease and related forms of dementia. Please visit MADRC.org to learn more about our current research opportunities, or call 617-643-5200 to find out how to join us in the fight against these brain diseases.

Study of Memory and Aging

Estamos buscando adultos mayores de 65 años para participar en nuestro estudio para entender cómo se desarrolla la pérdida de memoria en el cerebro humano. Aprende más.

We're recruiting Spanish-speaking adults over 65 to participate in our study to understand how memory loss develops in the human brain. Learn more.

Research on Memory and Aging in Black Adults

We encourage African American/Black adults over age 50, with or without memory concerns, to join our ongoing study of memory and aging. Learn more.